Basilea Pharmaceutica AG reported full-year (FY) 2025 total revenue of CHF 232.4 million, up 11%. Product revenue reached CHF 50.8 million, contract revenue was CHF 143.6 million, and other revenue totaled CHF 38.0 million. Operating profit stood at CHF 51.5 million for the period, reflecting a one-time CHF 12 million expense related to in-licensing ceftibuten-ledaborbactam; excluding this, operating profit would have exceeded the prior year. Net research and development expenses increased to CHF 105.9 million, and selling, general, and administrative expenses were CHF 35.6 million. The company reported a tripling of its net cash position to CHF 86.9 million and a 15% increase in royalty income. Key business highlights include continued progress in the phase 3 program with fosmanogepix and a strategic focus on treatments for severe bacterial and fungal infections. For FY 2026, Basilea expects a double-digit increase in both total revenue and operating profit, with total revenue anticipated to rise by approximately 10% and operating profit by 20%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602170115PRIMZONEFULLFEED1001165135) on February 17, 2026, and is solely responsible for the information contained therein.